[Lecithin:Cholesterol Acyltransferase Deficiency, from genes to therapy].

Abstract

LCAT synthesizes most of the plasma cholesteryl esters, and plays a major role in HDL metabolism. Mutations in the LCAT gene cause two syndromes, familial LCAT deficiency (FLD) and fish-eye disease (FED), both characterized by severe alterations in plasma lipoprotein profile. Renal disease is the major cause of morbidity and mortality in FLD cases, but an established therapy is not currently available. The present therapy of LCAT deficiency is mainly aimed at correcting the dyslipidemia associated with the disease and at delaying evolution of chronic nephropathy. LCAT deficiency represents a candidate disease for enzyme replacement therapy. In vitro and in vivo studies proved the efficacy of recombinant human LCAT (rhLCAT) in correcting dyslipidemia, and rhLCAT is presently under development.

• Authors: Fabio Lucca, Alice Ossoli, Giuliano Boscutti, Guido Franceschini, Laura Calabresi
• Journal: Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia (G Ital Nefrol) 2016 Malattie Metaboliche e Rene Vol. 33 Issue S68 ISSN: 1724-5990 [Electronic] Italy
• Vernacular Title: Deficit di lecitina:colesterolo aciltransferasi, dalla genetica alla terapia.
• PMID: 27960011 (Publication Type: Journal Article)

Topics

• Humans
• Lecithin Cholesterol Acyltransferase Deficiency (diagnosis, genetics, therapy)